Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from enabling innovation to second-guessing it. Alongside figures like Robert F. Kennedy Jr., who continues to elevate anti-vaccine rhetoric and cast doubt on long-settled scientific questions from his perch at the Department of Health and Human Services, Prasad is eroding the regulatory integrity that has for so long given America an edge in medical technology.
Read Full Article »
